Analyst Downgrade Impact: Recent discussions on social media have centered around a downgrade of Synopsys stock by a prominent analyst firm, sparking concern among investors. Many are highlighting potential headwinds for the company’s $1.75 billion IP business due to shifts in semiconductor resources toward AI chip production. This has led to a notable dip in stock price, with some expressing worry about long-term growth.
Nvidia Partnership Buzz: Another hot topic is Nvidia’s $2 billion investment in Synopsys as part of a multi-year partnership to advance AI and design engineering. Conversations reflect excitement over how this collaboration could position Synopsys as a key player in cutting-edge technology. However, opinions are mixed, with some questioning if the deal’s benefits will outweigh current industry challenges.
Note: This discussion summary was generated from an AI condensation of post data.
Synopsys Insider Trading Activity
Synopsys insiders have traded $SNPS stock on the open market 10 times in the past 6 months. Of those trades, 1 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $SNPS stock by insiders over the last 6 months:
- SUDHINDRA KANKANWADI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 15,873 shares for an estimated $7,837,408.
- SASSINE GHAZI (PRESIDENT AND CEO) sold 11,366 shares for an estimated $6,694,725
- SHELAGH GLASER (CFO) has made 0 purchases and 4 sales selling 7,312 shares for an estimated $3,913,745.
- JANET LEE (GC & Corporate Secretary) has made 0 purchases and 2 sales selling 500 shares for an estimated $260,000.
- ROBERT G PAINTER purchased 350 shares for an estimated $148,903
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Synopsys Revenue
Synopsys had revenues of $2.3B in Q4 2025. This is an increase of 37.83% from the same period in the prior year.
You can track SNPS financials on Quiver Quantitative's SNPS stock page.
Synopsys Congressional Stock Trading
Members of Congress have traded $SNPS stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $SNPS stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAN NEWHOUSE purchased up to $15,000 on 12/31.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 11/18, 10/09.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/13 and 1 sale worth up to $15,000 on 09/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Synopsys Hedge Fund Activity
We have seen 921 institutional investors add shares of Synopsys stock to their portfolio, and 515 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 3,120,401 shares (+20.7%) to their portfolio in Q3 2025, for an estimated $1,539,574,649
- MORGAN STANLEY added 2,600,089 shares (+139.5%) to their portfolio in Q3 2025, for an estimated $1,282,857,911
- BLACKROCK, INC. added 2,371,463 shares (+18.5%) to their portfolio in Q3 2025, for an estimated $1,170,056,129
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,001,274 shares (-37.6%) from their portfolio in Q3 2025, for an estimated $987,408,578
- VICTORY CAPITAL MANAGEMENT INC added 1,990,608 shares (+238.8%) to their portfolio in Q3 2025, for an estimated $982,146,081
- FMR LLC added 1,868,243 shares (+47.5%) to their portfolio in Q3 2025, for an estimated $921,772,413
- COATUE MANAGEMENT LLC added 1,809,127 shares (+inf%) to their portfolio in Q3 2025, for an estimated $892,605,170
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Synopsys Government Contracts
We have seen $380,206 of award payments to $SNPS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TO RENEW CODE V/ETD: $112,238
- PURCHASE SOFTWARE FOR TCAD FABRICATION PROCESS SIMULATION: $110,100
- SYNPLIFY BASE PERPETUAL MAINTENANCE: $43,940
- SYNOPSYS SYNPLIFY SOFTWARE LICENSE: $33,800
- .1. THE PURPOSE OF ORDER W56JSR-23-P-0009 IS TO PROVIDE SUBSCRIPTION FIRM-FIXED-PRICE (FFP) SYNOPSIS SYNP...: $33,420
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Synopsys Analyst Ratings
Wall Street analysts have issued reports on $SNPS in the last several months. We have seen 11 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Rosenblatt issued a "Buy" rating on 12/11/2025
- B of A Securities issued a "Buy" rating on 12/11/2025
- Citigroup issued a "Buy" rating on 11/24/2025
- Exane BNP Paribas issued a "Underperform" rating on 10/02/2025
- Mizuho issued a "Outperform" rating on 09/11/2025
- Morgan Stanley issued a "Overweight" rating on 09/11/2025
- Keybanc issued a "Overweight" rating on 09/10/2025
To track analyst ratings and price targets for Synopsys, check out Quiver Quantitative's $SNPS forecast page.
Synopsys Price Targets
Multiple analysts have issued price targets for $SNPS recently. We have seen 14 analysts offer price targets for $SNPS in the last 6 months, with a median target of $560.0.
Here are some recent targets:
- Clarke Jeffries from Piper Sandler set a target price of $520.0 on 01/13/2026
- Lee Simpson from Morgan Stanley set a target price of $550.0 on 12/12/2025
- Harlan Sur from JP Morgan set a target price of $650.0 on 12/11/2025
- Blair Abernethy from Rosenblatt set a target price of $560.0 on 12/11/2025
- Vivek Arya from B of A Securities set a target price of $560.0 on 12/11/2025
- Joe Quatrochi from Wells Fargo set a target price of $500.0 on 12/11/2025
- Jason Celino from Keybanc set a target price of $600.0 on 12/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
